|
|
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
skqfighting(fjtony163代发): 金币+20, 代发 2016-06-30 00:13:14
fjtony163: 翻译EPI+1, 代发 2016-06-30 00:13:20
|
As shown in the realease curve, the API release was fairly quick, about 60% was released in 3 hrs and completedly released by 48 hrs. In contrast, the API release from nanocapsules of Pluonic P123 copolymer was 11% in 3 hrs, which increased steadily after 24 hrs. The cummulative release was 75% by 48 hrs. Compared to free API, the Pluonic P123 nanocapsules showed an excellent slow release property. The Pluonic P123 nanocapsules as a drug carrier could achieve long blood circulation time due to its flexible and hydrophilic corona layer that improves the colloidal stability and suppresses the non-selective uptake of nanoparticles by the RES system, which enbales the passive delivery through the well known EPR effect, or targeted delivery to other organs and tissues, and release its cargo locally over time. Pluronic P123 is a biodegradable amphipathic block polymer with good biocompatibility, with no obvious toxicity and side effects. It has been reported that Pluronic P123 can reverse multidrug resistance phenotype of cancer cells and enhance treatment outcome. The in vivo PK and PD of PluronicP123 copolymer nanocapsule will need further studies in future. |
|
回复此楼